Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice
- PMID: 36106692
- PMCID: PMC9538859
- DOI: 10.1002/eji.202249913
Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice
Abstract
SARS-CoV-2 is a newly emerged coronavirus, causing the global pandemic of respiratory coronavirus disease (COVID-19). The type I interferon (IFN) pathway is of particular importance for anti-viral defense and recent studies identified that type I IFNs drive early inflammatory responses to SARS-CoV-2. Here, we use a mouse model of SARS-CoV-2 infection, facilitating viral entry by intranasal recombinant Adeno-Associated Virus (rAAV) transduction of hACE2 in wildtype (WT) and type I IFN receptor-1 deficient (Ifnar1-/- ) mice, to study the role of type I IFN signalling and innate immune responses during SARS-CoV-2 infection. Our data show that type I IFN signalling is essential for inducing anti-viral effector responses to SARS-CoV-2, control of virus replication, and to prevent enhanced disease. Furthermore, hACE2-Ifnar1-/- mice had increased gene expression of the chemokine Cxcl1 and airway infiltration of neutrophils as well as reduced and delayed production of monocyte-recruiting chemokine CCL2. hACE2-Ifnar1-/- mice showed altered recruitment of inflammatory myeloid cells to the lung upon SARS-CoV-2 infection, with a shift from Ly6C+ to Ly6C- expressing cells. Together, our findings suggest that type I IFN signalling deficiency results in a dysregulated innate immune response to SARS-CoV-2 infection.
Keywords: SARS-CoV-2; in vivo; innate immune response; myeloid cells; type I IFN.
© 2022 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
References
-
- O'Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A. et al., Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021. 590: 140-145.
-
- Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005. 5: 375-386.
-
- Trinchieri, G. Type I interferon: Friend or foe? J Exp Med 2010. 207: 2053-2063.
-
- Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W. C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X. et al., Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020. 181: 1036-1045.e9.
-
- Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H. et al., Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020. 369: 718-724.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous